<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03264794</url>
  </required_header>
  <id_info>
    <org_study_id>CTTQ-20161017</org_study_id>
    <nct_id>NCT03264794</nct_id>
  </id_info>
  <brief_title>the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)</brief_title>
  <official_title>Evaluation of the Efficacy of Domestic Gefitinib Tablets in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Using a Multicenter, Randomized, Positive Drug Gefitinib Pharmacodynamics and Pharmacodynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Famous Medical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Famous Medical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Gefitinib CTTQ production gefitinib and erlotinib sheet AstraZeneca imatinib sheet
           (trade name: Iressa ®) comparison, human pharmacokinetics and relative bioavailability
           of comparative studies which examine people in vivo pharmacokinetic behavior, provide
           the basis for clinical use.

        2. Evaluation CTTQ gefitinib imatinib sheet production efficacy and safety of Chinese
           patients with locally advanced or metastatic non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gefitinib plasma concentration</measure>
    <time_frame>0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration</time_frame>
    <description>After the use of gefitinib to reach the highest plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax time</measure>
    <time_frame>0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration</time_frame>
    <description>Taking the time required for the concentration of gefitinib to reach the peak</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration</time_frame>
    <description>The area between the axis of the coordinate and the time drug concentration curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t 1/2</measure>
    <time_frame>0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration</time_frame>
    <description>The time required for gefitinib to decrease by half the highest concentration in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>F</measure>
    <time_frame>0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration</time_frame>
    <description>Gefitinib absorbs the relative amount of blood into the cycle</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>trial group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gefitinib tablets (CTTQ），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gefitinib tablets (Yi Ruisha），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial</intervention_name>
    <description>Gefitinib Tab （CTTQ），First medication,250mg；</description>
    <arm_group_label>trial group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib tablets (Yi Ruisha），First medication</intervention_name>
    <description>Gefitinib tablets (Yi Ruisha），First medication,250mg；</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.</intervention_name>
    <description>From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）</description>
    <arm_group_label>trial group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients volunteered to participate in this study, signed informed consent;

          2. ≥18 years old; ECOG PS score: 0 ~ 1; expected survival period of more than 3 months;

          3. patients with locally advanced or metastatic non-small cell lung cancer diagnosed by
             histology or cytology, who can not receive radical surgery or radiotherapy; patients
             with measurable lesions(according to RECIST criteria);

          4. Detection of EGFR-positive exon 19 deletion or exon 21 (L858R) mutation was performed
             by providing a detectable specimen (tissue or cancerous pleural effusion) prior to
             enrollment;

          5. The main organ function within 7 days before treatment, meet the following criteria:

        (1) blood routine examination criteria (14 days without blood transfusion): A) hemoglobin≥
        90g / L; B) neutrophil absolute ≥ 1.5 × 109 / L; C) platelet ≥80 × 109 / L (2) biochemical
        tests to meet the following criteria: A) total bilirubin ≤ 1.5 times the upper limit of
        normal (ULN); B) alanine aminotransferase and aspartate aminotransferase AST ≤ 2.5ULN, such
        as liver metastasis, ALT and AST ≤ 5ULN; C) serum creatinine ≤ 1.5ULN or creatinine
        clearance ≥ 60ml / min; (3) Doppler ultrasound evaluation: left ventricular ejection
        fraction (LVEF) ≥ normal low (50%).

        6.Women of childbearing age should agree that contraceptive measures (such as intrauterine
        devices, birth control pills or condoms) must be used within the study period and within 6
        months after the end of the study; serum or urine pregnancy test is negative within 7 days
        prior to enrollment, And must be non-lactating patients; men should agree to patients who
        have contraceptive use during the study period and six months after the end of the study
        period.

        Exclusion Criteria:

          1. patients who have previously used EGFR-TKI drugs;

          2. small cell lung cancer (including small cell carcinoma and non-small cell carcinoma
             mixed lung cancer);

          3. central type, with empty lung squamous cell carcinoma, or with non-small cell lung
             cancer with hemoptysis (&gt; 50 ml / day) 4.5 years or at the same time with other
             malignancies, cured cervical carcinoma in situ, non-melanoma skin cancer and
             superficial bladder tumor except [Ta (non-invasive tumor), Tis (carcinoma in situ )
             And T1 (tumor infiltrating basement membrane)];

        5.Whole-body antitumor therapy was planned within 4 weeks prior to randomization or during
        the course of this study, including cytotoxic therapy, signal transduction inhibitors,
        immunotherapy (or use of mitogen at 6 weeks prior to administration of the test drug) C);
        6.patients with symptomatic or unstable brain metastases; 7.patients with any severe and /
        or uncontrolled disease, including: A) cirrhosis, acute or active hepatitis; B) history of
        immunodeficiency, including HIV-positive or other acquired, congenital immunodeficiency
        disease, or history of organ transplantation; C) patients with seizures and who need
        treatment; 8.active or uncontrollable serious infection (≥CTC AE Level 2 infection); 9.with
        a history of mental illness and can not quit or have mental disorders; 10.participated in
        other anti-tumor drug clinical trials within four weeks; 11.According to the judge's
        judgment, there is an impact on the absorption of oral drugs or serious harm to the safety
        of patients is not suitable for participation in the study of the situation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

